Understanding the adsorption of plasmid DNA and RNA molecules onto arginine-agarose chromatographic resin.
Adsorption
Arginine-agarose resin
Batch equilibrium
Plasmid DNA
RNA
Journal
Molecular biology reports
ISSN: 1573-4978
Titre abrégé: Mol Biol Rep
Pays: Netherlands
ID NLM: 0403234
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
received:
24
08
2021
accepted:
08
02
2022
pubmed:
19
2
2022
medline:
10
6
2022
entrez:
18
2
2022
Statut:
ppublish
Résumé
The production of nucleic acids (plasmid DNA or mRNA) in response to the development of new advanced vaccine platforms has greatly increased recently, mostly resulting from the pandemic situation. Due to the intended pharmaceutical use, nucleic acids preparations must fulfill all the required specifications in terms of purity and quality. Chromatography is a standard operation used to isolate these molecules from impurities, playing a central role in the manufacturing processes. However, the mechanism of nucleic acid adsorption in chromatographic resins is poorly understood, often leading to low adsorption capacities and a lack of specificity. Here we investigated the adsorption of plasmid DNA and RNA molecules onto arginine-agarose, a resin with potential for large-scale application. Equilibrium batch studies were performed through pre-purified samples, using arginine-based ligands by varying the adsorption conditions in the pH value range from 6.0 to 9.0. Langmuir and Freundlich isotherm models were used to describe the adsorption equilibrium. The best fit for both nucleic acids was achieved using the Freundlich model. The correct choice of pH showed critical for controlling the efficacy of arginine-nucleic acid interaction, due to its influence on the nucleic acid structures. This type of analysis is necessary for the improvement of the selectivity and binding capacities of the resins used for plasmid DNA or mRNA purification. The results presented here indicate that adsorption conditions can be tuned to enhance separation between pDNA and RNA, an important feature in the purification of nucleic acids for vaccine production.
Sections du résumé
BACKGROUND
BACKGROUND
The production of nucleic acids (plasmid DNA or mRNA) in response to the development of new advanced vaccine platforms has greatly increased recently, mostly resulting from the pandemic situation. Due to the intended pharmaceutical use, nucleic acids preparations must fulfill all the required specifications in terms of purity and quality. Chromatography is a standard operation used to isolate these molecules from impurities, playing a central role in the manufacturing processes. However, the mechanism of nucleic acid adsorption in chromatographic resins is poorly understood, often leading to low adsorption capacities and a lack of specificity.
METHODS AND RESULTS
RESULTS
Here we investigated the adsorption of plasmid DNA and RNA molecules onto arginine-agarose, a resin with potential for large-scale application. Equilibrium batch studies were performed through pre-purified samples, using arginine-based ligands by varying the adsorption conditions in the pH value range from 6.0 to 9.0. Langmuir and Freundlich isotherm models were used to describe the adsorption equilibrium. The best fit for both nucleic acids was achieved using the Freundlich model. The correct choice of pH showed critical for controlling the efficacy of arginine-nucleic acid interaction, due to its influence on the nucleic acid structures. This type of analysis is necessary for the improvement of the selectivity and binding capacities of the resins used for plasmid DNA or mRNA purification.
CONCLUSIONS
CONCLUSIONS
The results presented here indicate that adsorption conditions can be tuned to enhance separation between pDNA and RNA, an important feature in the purification of nucleic acids for vaccine production.
Identifiants
pubmed: 35178684
doi: 10.1007/s11033-022-07239-x
pii: 10.1007/s11033-022-07239-x
pmc: PMC8853897
doi:
Substances chimiques
RNA, Messenger
0
RNA
63231-63-0
DNA
9007-49-2
Sepharose
9012-36-6
Arginine
94ZLA3W45F
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3893-3901Subventions
Organisme : conselho nacional de desenvolvimento científico e tecnológico
ID : 305747/2020-7
Organisme : conselho nacional de desenvolvimento científico e tecnológico
ID : 304125/2018-0
Organisme : conselho nacional de desenvolvimento científico e tecnológico
ID : 307739/2015-5
Organisme : feder - programa operacional competitividade e internacionalização
ID : PTDC/BII-BBF/29496/2017
Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Nature B.V.
Références
Acc Chem Res. 2011 Dec 20;44(12):1270-9
pubmed: 21732619
J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Jun 15;1087-1088:149-157
pubmed: 29738965
Anal Biochem. 2008 Mar 15;374(2):432-4
pubmed: 18198126
J Sep Sci. 2012 Nov;35(22):3046-58
pubmed: 22961759
J Chromatogr B Analyt Technol Biomed Life Sci. 2013 Mar 1;919-920:67-74
pubmed: 23411021
J Chem Theory Comput. 2013 Feb 12;9(2):935-943
pubmed: 23525495
Microbiol Spectr. 2014 Dec;2(6):
pubmed: 26104457
J Sep Sci. 2008 Aug;31(14):2605-18
pubmed: 18461569
Biotechnol Prog. 2000 May-Jun;16(3):416-24
pubmed: 10835244
J Gene Med. 2007 May;9(5):392-402
pubmed: 17407167
Biotechnol Prog. 2019 Mar;35(2):e2765
pubmed: 30537363
J Chromatogr A. 2005 Mar 25;1069(1):3-22
pubmed: 15844479
J Chem Phys. 2014 Oct 28;141(16):165102
pubmed: 25362343
N Biotechnol. 2020 Nov 25;59:1-9
pubmed: 32622863
J Pharm Sci. 2013 Nov;102(11):3932-41
pubmed: 23996350
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Jan 15;1105:184-192
pubmed: 30597418
Recent Pat Biotechnol. 2007;1(2):151-66
pubmed: 19075838
Vaccines (Basel). 2013 Jun 25;1(3):225-49
pubmed: 26344110
Colloids Surf B Biointerfaces. 2011 Mar;83(1):1-9
pubmed: 21109408
J Sep Sci. 2014 Sep;37(17):2284-92
pubmed: 24917044
Methods Mol Biol. 2012;824:271-303
pubmed: 22160904
Science. 2020 Aug 14;369(6505):806-811
pubmed: 32434945
Biotechnol Prog. 1999 Jul-Aug;15(4):725-31
pubmed: 10441364
Hum Gene Ther. 2017 Oct;28(10):856-861
pubmed: 28826233
NPJ Vaccines. 2020 Feb 4;5:11
pubmed: 32047656
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246